Format

Send to

Choose Destination

See 1 citation found using an alternative search:

BioDrugs. 2017 Jun;31(3):239-249. doi: 10.1007/s40259-017-0221-x.

Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.

Author information

1
Glomerular Renal Diseases, Nephrology Department, Fundació Puigvert, Cartagena 340-350, 08025, Barcelona, Spain.
2
Hospital Puerta de Hierro, Madrid, Spain.
3
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
4
Hospital Universitario 12 de Octubre, Madrid, Spain.
5
Complexo Hospitalario Universitario de Ourense, Orense, Spain.
6
Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
7
Glomerular Renal Diseases, Nephrology Department, Fundació Puigvert, Cartagena 340-350, 08025, Barcelona, Spain. mmdiaz@fundacio-puigvert.es.

Abstract

BACKGROUND:

Patients with difficult-to-treat idiopathic nephrotic syndrome (INS), steroid-dependent nephrotic syndrome (SDNS), or frequently relapsing nephrotic syndrome (FRNS) require long-term immunosuppressive therapy. Rituximab offers an alternative treatment for patients with disease that has not responded to multiple therapies.

OBJECTIVE:

Our objective was to determine the efficacy and safety of rituximab in adult patients with difficult-to-treat (SDNS or FRNS) INS.

METHODS:

We performed a retrospective multicenter study that included 50 adults with difficult-to-treat INS in six Spanish centers. All patients were treated with steroids in combination with another immunosuppressant: 28 patients received rituximab as the additional treatment (rituximab group), and the other 22 patients not treated with rituximab served as the control group.

RESULTS:

Of the patients treated with rituximab, 23 (82%) experienced complete remission, 20 (71%) had no relapses after receiving rituximab, and 13 (46%) did not receive any immunosuppressant. Of those in the control group, 14 (63%) experienced complete remission, including eight without immunosuppressants (29%). The rituximab group experienced highly significant reductions in total number of relapses per year (p < 0.001), proteinuria (p = 0.03), steroid doses (p = 0.002), and tacrolimus doses (p = 0.001). Mean follow-up after rituximab was 31 ± 26 months (range 8-86). The need for steroids and other immunosuppressants to achieve sustained remission was lower in the rituximab group than in the control group.

CONCLUSIONS:

Rituximab treatment was safe and well tolerated. It effectively reduced the incidence of relapses and need for maintenance immunosuppressive therapy in adults with difficult-to-treat INS.

PMID:
28534103
DOI:
10.1007/s40259-017-0221-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center